Coagulopathy of Immunodermatologic Diseases
Trial Summary
What is the purpose of this trial?
This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and mild/latent/well-controlled immune-mediated skin diseases. A one-time sample from 15 general dermatology outpatients who do not have a known or suspected diagnosis of bullous diseases, immune-mediated dermatologic condition, or cutaneous malignancy will also be collected to serve as control. Blood samples from both participant populations will be analyzed for coagulation and inflammatory markers and compared. The results of this study may help inform future studies on the utility of analyzing coagulation and fibrinolysis profiles of patients with autoimmune skin diseases.
Research Team
Erin X Barrett, MD
Principal Investigator
University of Nebraska
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Sample Collection
Blood samples are collected from participants with active/poorly controlled and mild/latent/well-controlled immune-mediated skin diseases, as well as from control participants without immune-mediated dermatologic conditions.
Analysis
Blood samples are analyzed for coagulation and inflammatory markers and compared between participant groups.
Follow-up
Participants are monitored for safety and effectiveness after sample collection and analysis.
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Nebraska
Lead Sponsor